PF-06372865
目录号: PL02475 纯度: ≥98%
CAS No. :1614245-70-3
商品编号 规格 价格 会员价 是否有货 数量
PL02475-5mg 5mg ¥2410.00 请登录
PL02475-10mg 10mg ¥4018.00 请登录
PL02475-25mg 25mg ¥8840.00 请登录
PL02475-50mg 50mg ¥13661.00 请登录
PL02475-100mg 100mg ¥21698.00 请登录
PL02475-200mg 200mg 询价 询价
PL02475-500mg 500mg 询价 询价
PL02475-10mM*1mLinDMSO 10mM*1mLinDMSO ¥2652.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
PF-06372865
英文名称
PF-06372865
英文别名
Darigabat;7-Ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine;7-ethyl-4-[3-(4-ethylsulfonyl-2-methoxyphenyl)-4-fluorophenyl]imidazo[4,5-c]pyridazine;Darigabat [INN];7-Ethyl-4-[4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl]-7H-imidazo[4,5-c]pyridazine;O9BP19HZ3Q;GTPL9798;BDBM144227;TQ0078;example 4 [WO2014091368];PF06372865;US8952008, 4;7-Ethyl-4-(4'-(ethylsulf;PF-06372865
Cas No.
1614245-70-3
分子式
C22H21FN4O3S
分子量
440.49
包装储存
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
产品详情
PF-06372865 是一种具有口服活性的,α2/α3/α5 亚型选择性的 GABAA 正向变构调节剂 (PAM)。PF-06372865 是 α1/α2/α3/α5 亚基的高亲和力配体,对 α2,α1 PAM,α2 PAM 的 Ki 值分别为 2.9 nM,21 nM,134 nM,对 α4/α6 亚基的亲和力低。PF-06372865 可以透过血脑屏障 (BBB)。PF-06372865 具有抗焦虑活性,并且有用于癫痫研究的潜力。
生物活性
PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABA A positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABA A receptors containing α1/α2/α3/α5 subunits (K i s of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 can across the blood-brain barrier (BBB). PF-06372865 has anxiolytic activity and has the potential for epilepsy.
性状
Solid
IC50 & Target[1][2]
Ki: 2.9 nM (α2), 21 nM (α1 PAM) and 134 nM (α2 PAM)
体外研究(In Vitro)
PF-06372865 (compound 34) has Ki values of 0.18 nM, 2.9 nM, 1.1 nM, 18 nM for human GABAA α1β3γ2, α2β2γ2, α3β3γ2, α5β2γ2 and 0.34 nM, 4.58 nM for rat GABAA α1β3γ2, α2β2γ2.
has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
PF-06372865 (compound 34; 3, 10 mg/kg; orally; single dose) significantly increases the paw withdrawal threshold (PWT) in chronic constriction injury (CCI) animals.
PF-06372865 (0.3, 3, 10 mg/kg for mouse and 1, 3, 10 mg/kg for rat; orally) exhibits efficacy in two models of epilepsy, PTZ induced seizures (mouse), and amygdala kindling (rat).
PF-06372865 (0.1, 0.32, 1, 3.2 and 10 mg/kg; orally) has anxiolytic activity at 3.2 and 10 mg/kg in elevated plus maze (male C57Bl/6 mice).
PF-06372865 has a T 1/2 of 1.1 hours, a Cl p of 22 mL/min/kg, and a V ss of 2.1 L/kg for rats.
PF-06372865 has a T 1/2 of 0.9 hours, a Cl p of 29 mL/min/kg, and a V ss of 3.4 L/kg for dogs.
has not independently confirmed the accuracy of these methods.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
ClinicalTrial
参考文献
[1]. Owen RM, et al. Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865). J Med Chem. 2019 Jun 27;62(12):5773-5796.
溶解度数据
In Vitro: DMSO : 50 mg/mL (113.51 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2